LATE-BREAKING ABSTRACT POLICY
|Abstract submission opens||1 July 2013|
|Abstract submission deadline||16 August 2013, 17.00 (GMT)|
Late-breaking abstract submission will be allowed for authors to submit their breakthrough findings in the field of diabetes.
Authors should ONLY submit abstracts which comply with the following conditions:
- They should contain new research findings of special importance
- They Should NOT contain preliminary data
- Results published or likely to have been published before 6 December 2013 are not allowed.
Late-breaking abstract submission is only possible if the presenting author has paid the full applicable registration fee for the World Diabetes Congress before submitting the late-breaking abstract.
To submit a late breaking abstract please create or use your existing congress profile.
GUIDELINES FOR LATE-BREAKING ABSTRACT SUBMISSION
Submission mode: Late-breaking abstract submission is only possible online at www.worlddiabetescongress.org. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 16 August 2013, 17.00 Greenwich Mean Time (GMT).
IDF Congress Profile: In order to submit an abstract, a congress profile must be created to register for the congress and allowing entry into the online abstract submission module. The presenting author must ensure accurate contact details are entered. One or several abstracts can be submitted by logging into this congress profile.
Submitting author / Presenting author: The submitting author must be the presenting author. The presenting author must be registered before submitting a late-breaking abstract. If the presenting author is not registered their abstract will not be sent to the Programme Committee for review.
Number of submissions: There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An unlimited number of abstracts can be submitted and presented by an individual.
Language: All abstracts must be submitted in English. Should English not be your first language, you may wish to have your abstract examined by a native English speaker prior to submission.
Accuracy of content: Submitted abstracts may be edited online prior to the abstract submission deadline: 16 August 2013, 17.00 Greenwich Mean Time (GMT). Abstracts CANNOT be edited or revised in any way after the deadline. All accepted abstracts will be published as submitted by the author. The responsibility for the submission of an accurate and precise abstract lies solely with the author.
Originality of abstracts: Work published elsewhere before 6 December 2013 should NOT be resubmitted to the World Diabetes Congress. However, previously published work can be resubmitted provided there are new methods and/or findings.
Disclosure of interests: Any financial relationships with commercial entities in the products or processes described in the work must be correctly stated.
Regulatory approval: The presenting author confirms that local regulatory approval has been obtained as required by local laws.
Author consent: The presenting author declares all authors have read and approved the submitted work.
Copyright transfer: Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module. For rejected abstracts, the copyright reverts back to the authors.
Category and stream: There are various categories that have been defined for the abstract programme along with five streams. Ensure that you select the MOST relevant stream and then select the ONE category which BEST describes the content of your abstract. Categories are used for reviewing and indexing purposes.
- The title is limited to 120 characters excluding spaces and should be brief and relevant. Special characters should NOT be used in your title but spelt out instead (e.g. ß is beta; ω is omega).
- Only use standard abbreviations and generic drug names in the title.
Authors: Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.
- Structure: the abstract, if applicable, to include aims, methods, results and discussion/conclusion.
- Font, size and style will be automatically configured by the system.
- Tables will be accepted in the submission field and count towards the character limit. The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. Graphs, figures and photographs are NOT allowed.
- The length of the abstract is limited to 2100 characters excluding spaces. Only the abstract body and any inserted tables count towards the character limit. The character count displayed beneath the submission field is final and undisputable.
- Only commonly accepted abbreviations should be used (e.g. OGTT, IGT, ACEI). Treatment groups or drug names should NOT be abbreviated. Less widely recognized abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
- Only approved and generic (non-proprietary) drug names should be used.
- Do NOT enter the title, authors, or grant information into the abstract text submission field and exclude any references from the abstract body.
SELECTION AND NOTIFICATION PROCESS
- Selection: All submitted late-breaking abstracts are reviewed by the Programme Committee. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorize any accepted abstract. The decision of the Programme Committee is final and irrevocable.
- Notification: Notice of acceptance or rejection of submitted late-breaking abstracts will be sent to the presenting author by the end of September 2013. It is the responsibility of the presenting author to inform all other authors of the status of the abstract. A presenting author may also check their congress profile to see the status of the abstract.